IntAct European Bioinformatics Institute IntAct intact http://www.ebi.ac.uk/ http://www.ebi.ac.uk/intact/query/${ac} EBI-[0-9]+|IA:[0-9]+ INTerAction database (IntAct) provides an open source database and toolkit for the storage, presentation and analysis of molecular interactions. http://www.ebi.ac.uk/intact European Bioinformatics Institute; Wellcome Trust Genome Campus; Hinxton, Cambridge; CB10 1SD; United Kingdom http://www.ebi.ac.uk/intact/ Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Cell (0092-8674) 2010 imex curation Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk 29-Mar-2010: Contacted by JYOTI. jyoti Only protein-protein interactions 20 human-wm1791c Homo sapiens wm1791c Human WM1791c melanoma cells anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk Accepted 2010-MAR-26 by JYOTI. 29-Mar-2010: Contacted by JYOTI. Cell (0092-8674) 2010 jyoti Only protein-protein interactions 20 imex curation Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Cell (0092-8674) 2010 imex curation Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk 29-Mar-2010: Contacted by JYOTI. jyoti Only protein-protein interactions 20 human-pmwk Human PMWK melanoma cells pmwk Human PMWK melanoma cells anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk Accepted 2010-MAR-26 by JYOTI. 29-Mar-2010: Contacted by JYOTI. Cell (0092-8674) 2010 jyoti Only protein-protein interactions 20 imex curation Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Cell (0092-8674) 2010 imex curation Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk 29-Mar-2010: Contacted by JYOTI. jyoti Only protein-protein interactions 20 human-hct116 Human colon carcinoma HCT116 cells hct116 Human colon carcinoma line HCT116 anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk Accepted 2010-MAR-26 by JYOTI. 29-Mar-2010: Contacted by JYOTI. Cell (0092-8674) 2010 jyoti Only protein-protein interactions 20 imex curation Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Cell (0092-8674) 2010 imex curation Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk 29-Mar-2010: Contacted by JYOTI. jyoti Only protein-protein interactions 20 human-d04 Human D04 cells d04 D04 melanoma cells anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk Accepted 2010-MAR-26 by JYOTI. 29-Mar-2010: Contacted by JYOTI. Cell (0092-8674) 2010 jyoti Only protein-protein interactions 20 imex curation Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Cell (0092-8674) 2010 imex curation Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk 29-Mar-2010: Contacted by JYOTI. jyoti Only protein-protein interactions 20 human-mm415 Human MM415 cells mm415 MM415 human melanoma cell line anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk Accepted 2010-MAR-26 by JYOTI. 29-Mar-2010: Contacted by JYOTI. Cell (0092-8674) 2010 jyoti Only protein-protein interactions 20 imex curation Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Cell (0092-8674) 2010 imex curation Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk 29-Mar-2010: Contacted by JYOTI. jyoti Only protein-protein interactions 20 human-wm852 Human WM852 cells wm852 WM852 human melonoma cell line anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk Accepted 2010-MAR-26 by JYOTI. 29-Mar-2010: Contacted by JYOTI. Cell (0092-8674) 2010 jyoti Only protein-protein interactions 20 imex curation Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Cell (0092-8674) 2010 imex curation Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk 29-Mar-2010: Contacted by JYOTI. jyoti Only protein-protein interactions 20 human-mm485 Human MM485 cells mm485 MM485 human melanoma cell line anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk Accepted 2010-MAR-26 by JYOTI. 29-Mar-2010: Contacted by JYOTI. Cell (0092-8674) 2010 jyoti Only protein-protein interactions 20 imex curation Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Cell (0092-8674) 2010 imex curation Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk 29-Mar-2010: Contacted by JYOTI. jyoti Only protein-protein interactions 20 mouse-melanoma Mouse melanoma melanoma Melanoma anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk Accepted 2010-MAR-26 by JYOTI. 29-Mar-2010: Contacted by JYOTI. Cell (0092-8674) 2010 jyoti Only protein-protein interactions 20 imex curation Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Cell (0092-8674) 2010 imex curation Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk 29-Mar-2010: Contacted by JYOTI. jyoti Only protein-protein interactions 20 human-sw620 Human caucasian colon adenocarcinoma SW620 cells sw620 Human caucasian colon adenocarcinoma SW620 cells anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk Accepted 2010-MAR-26 by JYOTI. 29-Mar-2010: Contacted by JYOTI. Cell (0092-8674) 2010 jyoti Only protein-protein interactions 20 imex curation Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Cell (0092-8674) 2010 imex curation Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk 29-Mar-2010: Contacted by JYOTI. jyoti Only protein-protein interactions 20 human-d04 Human D04 cells d04 D04 melanoma cells anti tag coip anti tag coimmunoprecipitation anti tag coip western blot western blot Immuno blot Immuno blot Heidorn SJ., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho JS., Springer CJ., Pritchard C., Marais R. Cancer - Interactions investigated in the context of cancer richard.marais@icr.ac.uk Accepted 2010-MAR-26 by JYOTI. 29-Mar-2010: Contacted by JYOTI. Cell (0092-8674) 2010 jyoti Only protein-protein interactions 20 imex curation braf_human Serine/threonine-protein kinase B-raf BRAF BRAF1 RAFB1 v-Raf murine sarcoma viral oncogene homolog B1 p94 Proto-oncogene B-Raf protein protein human Homo sapiens Human MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH DIP protein P15056 original sequence version: 182 DIP protein P15056 original sequence version: 133 DIP protein P15056 original sequence version: 147 DIP protein P15056 original sequence version: 173 DIP protein P15056 original sequence version: 178 DIP protein P15056 original sequence version: 188 DIP protein P15056 original sequence version: 193 DIP protein P15056 original sequence version: 195 DIP protein P15056 original sequence version: 146 DIP protein P15056 original sequence version: 153 0798C2AAB487E813 raf1_human RAF proto-oncogene serine/threonine-protein kinase RAF1 RAF Proto-oncogene c-RAF Raf-1 protein protein human Homo sapiens Human MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF DIP protein P04049 original sequence version: 117 DIP protein P04049 original sequence version: 106 DIP protein P04049 original sequence version: 114 DIP protein P04049 original sequence version: 141 DIP protein P04049 original sequence version: 142 DIP protein P04049 original sequence version: 147 DIP protein P04049-1 original sequence version: 136 DIP protein P04049 original sequence version: 136 DIP protein P04049 original sequence version: 153 DIP protein P04049 original sequence version: 150 DIP protein P04049 original sequence version: 164 DIP protein P04049 original sequence version: 172 DIP protein P04049-1 original sequence version: 172 DIP protein P04049 original sequence version: 184 DIP protein P04049 original sequence version: 188 DIP protein P04049 original sequence version: 195 EF821B5349711BC3 raf1_mouse RAF proto-oncogene serine/threonine-protein kinase Raf1 Craf Proto-oncogene c-RAF Raf-1 protein protein mouse Mus musculus Mouse MEHIQGAWKTISNGFGLKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDSSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLQEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTVGDSGVPAPPSFPMRRMRESVSRMPASSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLHVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPGSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQLQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDDNPFSFQSDVYSYGIVLYELMAGELPYAHINNRDQIIFMVGRGYASPDLSRLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF DIP protein Q99N57 original sequence version: 97 DIP protein Q99N57 original sequence version: 132 DIP protein Q99N57 original sequence version: 92 B70104AEF51C44A5 braf_mouse Serine/threonine-protein kinase B-raf Braf B-raf Proto-oncogene B-Raf protein protein mouse Mus musculus Mouse MAALSGGGGSSSGGGGGGGGGGGGGDGGGGAEQGQALFNGDMEPEAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLVFQTPTDASRNNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPVPQEEASFPETALPSGSSSAPPSDSTGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSSSEDRSRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGGFPVH DIP protein P28028 original sequence version: 109 0643D7F6C44A9A05 braf-raf1-1 5 12 unspecified role unspecified role prey prey 11 unspecified role unspecified role bait bait physical association physical association Sorafenib (class II (inactive conformation binder) Raf inhibitor) 885-A selective BRAf inhibitor Fig. 2A braf-raf1-2 7 12 unspecified role unspecified role prey prey 11 unspecified role unspecified role bait bait physical association physical association Sorafenib (class II (inactive conformation binder) Raf inhibitor) 885-A selective BRAf inhibitor Fig. 2A braf-raf1-3 4 11 unspecified role unspecified role bait bait 12 unspecified role unspecified role prey prey physical association physical association Sorafenib (class II (inactive conformation binder) Raf inhibitor) 885-A selective BRAF inhibitor Fig. 2A braf-raf1-4 6 11 unspecified role unspecified role bait bait 12 unspecified role unspecified role prey prey physical association physical association Sorafenib (class II (inactive conformation binder) Raf inhibitor) 885-A selective BRAF inhibitor Fig. 2A braf-raf1-5 5 11 unspecified role unspecified role prey prey 12 unspecified role unspecified role bait bait physical association physical association Sorafenib (class II (inactive conformation binder) Raf inhibitor) 885-A selective BRAf inhibitor Fig. 2A braf-raf1-6 7 11 unspecified role unspecified role prey prey 12 unspecified role unspecified role bait bait physical association physical association Sorafenib (class II (inactive conformation binder) Raf inhibitor) 885-A selective BRAf inhibitor Fig. 2A braf-raf1-7 4 11 unspecified role unspecified role prey prey 12 unspecified role unspecified role bait bait physical association physical association Sorafenib (class II (inactive conformation binder) Raf inhibitor) 885-A selective BRAf inhibitor Fig. 2A, 2B, 3F, Supp Fig. 4B The MEK inhibitor PD184352 stabilizes BRAF binding to CRAF in the presence of the BRAF inhibitor PLX4720 BRAF bound to CRAF is hyperphosphorylated through MEK-ERK-dependent and MEK-ERK-independent mechanisms, but it appears that this phosphorylation is not required for BRAF binding to CRAF. Pan-RAF inhibitor ZM336372 an-RAF inhibitor RAF265 braf-raf1-8 6 12 unspecified role unspecified role bait bait 11 unspecified role unspecified role prey prey physical association physical association Sorafenib (class II (inactive conformation binder) Raf inhibitor) 885-A selective BRAf inhibitor Fig. 2A braf-raf1-9 9 12 unspecified role unspecified role prey prey 11 unspecified role unspecified role bait bait physical association physical association Sorafenib (class II (inactive conformation binder) Raf inhibitor) 885-A selective BRAF inhibitor Fig. 2C In addition to inducing BRAF binding to CRAF in NRAS mutant cells, 885-A and sorafenib also induce this binding in WM1791c melanoma cells and in SW620 and HCT116 colorectal carcinoma cells (Figure 2C), braf-raf1-10 9 11 unspecified role unspecified role prey prey 12 unspecified role unspecified role bait bait physical association physical association Sorafenib (class II (inactive conformation binder) Raf inhibitor) 885-A selective BRAF inhibitor Fig. 2C In addition to inducing BRAF binding to CRAF in NRAS mutant cells, 885-A and sorafenib also induce this binding in WM1791c melanoma cells and in SW620 and HCT116 colorectal carcinoma cells (Figure 2C), braf-raf1-11 3 12 unspecified role unspecified role prey prey 11 unspecified role unspecified role bait bait physical association physical association Sorafenib (class II (inactive conformation binder) Raf inhibitor) 885-A selective BRAF inhibitor Fig. 2C In addition to inducing BRAF binding to CRAF in NRAS mutant cells, 885-A and sorafenib also induce this binding in WM1791c melanoma cells and in SW620 and HCT116 colorectal carcinoma cells (Figure 2C), braf-raf1-12 3 11 unspecified role unspecified role prey prey 12 unspecified role unspecified role bait bait physical association physical association Sorafenib (class II (inactive conformation binder) Raf inhibitor) 885-A selective BRAF inhibitor Fig. 2C In addition to inducing BRAF binding to CRAF in NRAS mutant cells, 885-A and sorafenib also induce this binding in WM1791c melanoma cells and in SW620 and HCT116 colorectal carcinoma cells (Figure 2C), braf-raf1-13 1 12 unspecified role unspecified role prey prey 11 unspecified role unspecified role bait bait physical association physical association Sorafenib (class II (inactive conformation binder) Raf inhibitor) 885-A selective BRAF inhibitor Fig. 2C In addition to inducing BRAF binding to CRAF in NRAS mutant cells, 885-A and sorafenib also induce this binding in WM1791c melanoma cells and in SW620 and HCT116 colorectal carcinoma cells (Figure 2C), braf-raf1-14 1 11 unspecified role unspecified role prey prey 12 unspecified role unspecified role bait bait physical association physical association Sorafenib (class II (inactive conformation binder) Raf inhibitor) 885-A selective BRAF inhibitor Fig. 2C In addition to inducing BRAF binding to CRAF in NRAS mutant cells, 885-A and sorafenib also induce this binding in WM1791c melanoma cells and in SW620 and HCT116 colorectal carcinoma cells (Figure 2C), braf-raf1-15 10 12 unspecified role unspecified role bait bait n-terminal myc tag myc tag EUKLISEED epitope tag EUKLISEED epitope tag undetermined undetermined sequence position undetermined undetermined undetermined sequence position undetermined P04049:p.Arg89Leu mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing certain certain sequence position certain certain certain sequence position certain R L Wed May 02 19:31:06 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'arg89leu' Tue Jun 30 20:18:13 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Arg89Leu' 11 unspecified role unspecified role prey prey physical association physical association 885-A selective BRAF inhibitor Fig. 3A Myc-tagged CRAF was immunoprecipitated (IP) and the immunocomplexes were western blotted (WB) for endogenous BRAF or myc-CRAF. braf-raf1-16 10 11 unspecified role unspecified role bait bait n-terminal myc tag myc tag EUKLISEED epitope tag EUKLISEED epitope tag undetermined undetermined sequence position undetermined undetermined undetermined sequence position undetermined P15056:p.Arg188Leu mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing mutation analysis mutation analysis certain certain sequence position certain certain certain sequence position certain R L Wed May 02 18:01:06 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'arg188leu' Tue Jun 30 16:34:30 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Arg188Leu' 12 unspecified role unspecified role prey prey physical association physical association 885-A selective BRAF inhibitor Fig. 3B, 4D Myc-tagged CRAF was immunoprecipitated (IP) and the immunocomplexes were western blotted (WB) for endogenous BRAF or myc-CRAF. braf-raf1-17 2 12 unspecified role unspecified role bait bait 11 unspecified role unspecified role prey prey physical association physical association 885-A selective BRAF inhibitor Fig. 3D Endogenous CRAF was immunoprecipitated (IP) and the precipitates were western blotted (WB) for BRAF and CRAF. braf-raf1-18 4 12 unspecified role unspecified role bait bait 11 unspecified role unspecified role prey prey n-terminal myc tag myc tag EUKLISEED epitope tag EUKLISEED epitope tag undetermined undetermined sequence position undetermined undetermined undetermined sequence position undetermined P15056:p.Thr529Asn mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing mutation analysis mutation analysis certain certain sequence position certain certain certain sequence position certain T N Wed May 02 17:36:58 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'thr529asn' Tue Jun 30 15:58:31 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Thr529Asn' physical association physical association 885-A selective BRAf inhibitor Fig. 4C The endogenous CRAF was immunoprecipitated and the immunocomplexes were western blotted for myc-BRAF or endogenous CRAF. Thr529Asn mutation of BRAf appears to make the protein insensitive to 885-A treatment. braf-raf1-19 10 11 unspecified role unspecified role prey prey 12 unspecified role unspecified role bait bait n-terminal flag tag flag tag FLAG-tagged FLAG DYKDDDDKV epitope tag DYKDDDDKV epitope tag FLAG FLAG-tagged undetermined undetermined sequence position undetermined undetermined undetermined sequence position undetermined P04049:p.Arg89Leu mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing certain certain sequence position certain certain certain sequence position certain R L Wed May 02 16:19:39 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'arg89leu' Tue Jun 30 17:50:06 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Arg89Leu' physical association physical association 885-A selective BRAF inhibitor Fig. 4H Myc-tagged CRAF was immunoprecipitated (IP) and the immunocomplexes were western blotted (WB) for endogenous BRAF or myc-CRAF. Sorafenib, a selective BRAF inhibitor braf-raf1-20 8 13 unspecified role unspecified role bait bait 14 unspecified role unspecified role prey prey P28028:p.Asp579Ala mutation mutation certain certain sequence position certain certain certain sequence position certain D A Wed May 02 16:22:50 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'asp631ala' Tue Jun 30 19:54:01 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Asp631Ala' Mon Mar 01 11:47:32 GMT 2021 This feature has been corrected as a result of our quality control procedures. The original label was 'P28028:p.Asp631Ala' physical association physical association Endogenous CRAF was immunoprecipitated (IP) from cells derived from a tumor from a G12DKras/D594ABraf mouse Fig. 6E